NALOXONE by Hikma is clinical pharmacology complete or partial reversal of opioid depression naloxone prevents or reverses the effects of opioids including respiratory depression, sedation and hypotension. First approved in 1985.
Drug data last refreshed 5h ago
CLINICAL PHARMACOLOGY Complete or Partial Reversal of Opioid Depression Naloxone prevents or reverses the effects of opioids including respiratory depression, sedation and hypotension. Also, naloxone can reverse the psychotomimetic and dysphoric effects of agonist-antagonists, such as pentazocine.…
Worked on NALOXONE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
Blood Naloxone Levels Following Intradermal Injection in Humans
Clinical Decision Support to Improve System Naloxone Co-prescribing
Vending Machine Naloxone Distribution for Your Community (VENDY)